Compare Recursion Pharmaceuticals Inc (RXRX) vs Invesco Solar ETF (TAN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Recursion Pharmaceuticals Inc vs Invesco Solar ETF — how do they compare? Recursion Pharmaceuticals Inc trades at $3.99 (market cap $2.14B), while Invesco Solar ETF trades at $43.76 (market cap $894.08M). The key difference: Recursion Pharmaceuticals Inc is far larger — about 2.4× Invesco Solar ETF's market cap, and Recursion Pharmaceuticals Inc is trading nearer its 52-week high, Invesco Solar ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Recursion Pharmaceuticals Inc for 22 Days and Invesco Solar ETF for 34 Days on average.
| RXRX | TAN | |
|---|---|---|
Market Cap | $2.14B | $894.08M |
Volume | 30,789,535 | 370,994 |
Sector | Health | Sector/Thematic |
52-Week High | $6.79 | $73.95 |
52-Week Low | $2.84 | $43.00 |
Typical Hold Time | 22 Days | 34 Days |
Enterprise Value | $1.66B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RXRX trades at $4.27, down 7.78% today, with technical indicators showing a bullish trend despite recent weakness. The company reported Q2 2026 earnings miss after two consecutive beats, with revenue declining to $54 million in 2026 from $74 million in 2025. While maintaining a negative net income margin of -961.97%, RXRX continues to expand its AI-powered drug discovery platform through strategic partnerships with Tempus and Roche.
The stock presents high-risk growth potential with strong analyst support (40% buy rating) but faces significant execution challenges. Investment appeal hinges on successful pipeline development and commercialization of AI drug discovery technology, though persistent losses and declining revenue create substantial downside risk for shareholders.
TAN (Invesco Solar ETF) is trading at $43.53, down 1.96% amid sector-wide pressure from high borrowing costs impacting solar project financing. Technical indicators show a bearish trend with moving averages signaling sell pressure, while oscillators remain neutral. The ETF faces headwinds from solar industry volatility, price deflation, and margin erosion, having underperformed the S&P 500 by 112% over five years according to Seeking Alpha analysis from August 2026.
Outlook remains challenging with persistent sector headwinds including interest rate sensitivity and market saturation risks. Investment opportunity exists in long-term renewable energy transition, but requires tolerance for high volatility and deeper drawdowns compared to traditional energy ETFs. Key risks include policy uncertainty, grid adaptation costs, and competitive pressure from broader clean energy alternatives.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →About Invesco Solar ETF
TAN is a thematic ETF that tracks the MAC Global Solar Energy Index. It provides targeted exposure to the global solar industry, including manufacturers of solar panels, installers, and component suppliers like Enphase and First Solar.
Read more on TAN →
